Biontech, Pfizer Raise 2021 Vaccine Target By More Than 50%

Pfizer Inc. and German biotechnology player BioNTech SE have raised their anticipated 2021 vaccine production from 1.3 billion to 2.0 billion, which is more than 50%, catering to the increasing global demand. BioNTech informed the same via a demonstrative presentation at a healthcare conference on 11 January 2021. 

The firms, in various packs with different countries, have already said yes to provide more than 1 billion doses of the vaccine.  

While the European Union in the past week, has asked to double its supply of Pfizer-BioNTech shots to 600 million, the US has asked for 200 million doses.

As per the media sources, the increased production forecast is the result of freshly opened production lines along with a major development in the vaccine distribution process.

The company is using the ‘low dead space’ syringe, which lets six doses of the vaccine to be extracted, opposite to the standard five. The new syringe restricts the amount of wastage in the administration of the vaccine, leaving the excess to be used on another patient.

In the Conference, BioNTech revealed that now, around 2 billion doses can be delivered by the end of 2021.

Meanwhile, it should be noted that early testing results by Pfizer reveal that the vaccine is able to protect against the new variant of the coronavirus.

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.



Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.



Rated 4.3/5 based on 904 Reviews at Google My Business
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK